173 related articles for article (PubMed ID: 35833296)
21. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
Yang K; Xu J; Liu Q; Li J; Xi Y
Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
[TBL] [Abstract][Full Text] [Related]
22. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
Hu B; Jacobs R; Ghosh N
Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of PDL1 expression in pancreatic cancer.
Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
[TBL] [Abstract][Full Text] [Related]
24. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.
Patel SS; Weirather JL; Lipschitz M; Lako A; Chen PH; Griffin GK; Armand P; Shipp MA; Rodig SJ
Blood; 2019 Dec; 134(23):2059-2069. PubMed ID: 31697809
[TBL] [Abstract][Full Text] [Related]
25. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
26. Classification of tumor microenvironment immune types based on immune response-associated gene expression.
Kondou R; Iizuka A; Nonomura C; Miyata H; Ashizawa T; Nagashima T; Ohshima K; Urakami K; Kusuhara M; Yamaguchi K; Akiyama Y
Int J Oncol; 2019 Jan; 54(1):219-228. PubMed ID: 30387832
[TBL] [Abstract][Full Text] [Related]
27. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
28. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
29. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
Fonseca R; Salgado RM; Borges da Silva H; do Nascimento RS; D'Império-Lima MR; Alvarez JM
Front Immunol; 2018; 9():997. PubMed ID: 29867974
[TBL] [Abstract][Full Text] [Related]
30. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
31. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
33. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
[TBL] [Abstract][Full Text] [Related]
34. Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment.
Ferrarini I; Rigo A; Zamò A; Vinante F
Leuk Lymphoma; 2019 Dec; 60(14):3395-3405. PubMed ID: 31304817
[TBL] [Abstract][Full Text] [Related]
35. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.
Ameli F; Shajareh E; Mokhtari M; Kosari F
BMC Cancer; 2022 Aug; 22(1):848. PubMed ID: 35922773
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings.
Gupta GK; Agrawal T; Pilichowska M
BMC Cancer; 2020 Jun; 20(1):535. PubMed ID: 32513132
[TBL] [Abstract][Full Text] [Related]
37. Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain.
Zhang A; Wang S; Sun Y; Zhang Y; Zhao L; Yang Y; Zhang Y; Xu L; Lei Y; Du J; Chen H; Duan L; He M; Shi L; Liu L; Wang Q; Hu L; Zhang B
Exp Hematol Oncol; 2023 Sep; 12(1):85. PubMed ID: 37777797
[TBL] [Abstract][Full Text] [Related]
38. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma.
Schreck S; Friebel D; Buettner M; Distel L; Grabenbauer G; Young LS; Niedobitek G
Hematol Oncol; 2009 Mar; 27(1):31-9. PubMed ID: 18924115
[TBL] [Abstract][Full Text] [Related]
40. Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
Hartmann S; Soltani AS; Bankov K; Bein J; Hansmann ML; Rosenwald A; Bernd HW; Feller A; Ott G; Möller P; Stein H; Klapper W; Borchmann P; Engert A; Eichenauer DA
Br J Haematol; 2022 Nov; 199(3):382-391. PubMed ID: 35880396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
